Do analysts prefer RDHL or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is RDHL or SCNI more profitable?

Company Net Margins Return on Equity Return on Assets Redhill Biopharma N/A N/A N/A Scinai Immunotherapeutics N/A N/A N/A

Do analysts prefer SCNI or ALZN?

Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,313.79%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is SCNI or ALZN more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Alzamend Neuro N/A -177.52% -140.41%

Do analysts rate SCNI or CAPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Capstone Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SCNI or REVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Revelation Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNI or REVB more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Revelation Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Revelation Biosciences N/A -107.65% -87.98%

Do analysts rate DCOY or SCNI?

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than Scinai Immunotherapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DCOY or SCNI more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -395.42% -193.30% Scinai Immunotherapeutics N/A N/A N/A

Scinai Immunotherapeutics (SCNI) Competitors

$0.27 0.00 (0.00%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$0.27 0.00 (-1.63%)

As of 07/2/2026 05:39 PM Eastern

Compare

SCNI vs. RDHL, ALZN, CAPS, REVB, and DCOY

Should you buy Scinai Immunotherapeutics stock or one of its competitors? MarketBeat compares Scinai Immunotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Scinai Immunotherapeutics include Redhill Biopharma (RDHL), Alzamend Neuro (ALZN), Capstone Therapeutics (CAPS), Revelation Biosciences (REVB), and Decoy Therapeutics (DCOY). These companies are all part of the "pharmaceutical products" industry.

How does Scinai Immunotherapeutics compare to Redhill Biopharma?

Redhill Biopharma (NASDAQ:RDHL) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Redhill Biopharma has higher earnings, but lower revenue than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00
Scinai Immunotherapeutics	$1.21M	0.88	-$8.31M	-$1.06	N/A

7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Redhill Biopharma	N/A	N/A	N/A
Scinai Immunotherapeutics	N/A	N/A	N/A

In the previous week, Redhill Biopharma's average media sentiment score of 0.00 equaled Scinai Immunotherapeutics'average media sentiment score.

Company	Overall Sentiment
Redhill Biopharma	Neutral
Scinai Immunotherapeutics	Neutral

Redhill Biopharma has a beta of 4.98, meaning that its share price is 398% more volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market.

Summary

Redhill Biopharma beats Scinai Immunotherapeutics on 5 of the 8 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Alzamend Neuro?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Scinai Immunotherapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Alzamend Neuro	N/A	-177.52%	-140.41%

In the previous week, Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Alzamend Neuro	Neutral

Alzamend Neuro has lower revenue, but higher earnings than Scinai Immunotherapeutics. Alzamend Neuro is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.21M	0.88	-$8.31M	-$1.06	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,313.79%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts plainly believe Alzamend Neuro is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Scinai Immunotherapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market.

Summary

Scinai Immunotherapeutics beats Alzamend Neuro on 8 of the 12 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Capstone Therapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Capstone Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Capstone Therapeutics	Neutral

Scinai Immunotherapeutics has a net margin of 0.00% compared to Capstone Therapeutics' net margin of -41.26%. Scinai Immunotherapeutics' return on equity of 0.00% beat Capstone Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Capstone Therapeutics	-41.26%	-114.15%	-39.74%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Capstone Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scinai Immunotherapeutics has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Capstone Therapeutics has a beta of -1.51, meaning that its share price is 251% less volatile than the broader market.

Scinai Immunotherapeutics has higher earnings, but lower revenue than Capstone Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.21M	0.88	-$8.31M	-$1.06	N/A
Capstone Therapeutics	$51.62M	0.08	-$21.23M	-$3.37	N/A

Summary

Scinai Immunotherapeutics beats Capstone Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Revelation Biosciences?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Scinai Immunotherapeutics' return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Revelation Biosciences	N/A	-107.65%	-87.98%

Scinai Immunotherapeutics has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Revelation Biosciences has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 4.8% of Revelation Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Revelation Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scinai Immunotherapeutics has higher revenue and earnings than Revelation Biosciences. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.21M	0.88	-$8.31M	-$1.06	N/A
Revelation Biosciences	N/A	N/A	-$8.91M	-$39.48	N/A

In the previous week, Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Revelation Biosciences'average media sentiment score.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Revelation Biosciences	Neutral

Summary

Scinai Immunotherapeutics beats Revelation Biosciences on 8 of the 9 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Decoy Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Scinai Immunotherapeutics has higher revenue and earnings than Decoy Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Scinai Immunotherapeutics	$1.21M	0.88	-$8.31M	-$1.06	N/A

Decoy Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 310.40%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than Scinai Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market.

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 1.7% of Decoy Therapeutics shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Decoy Therapeutics had 5 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 5 mentions for Decoy Therapeutics and 0 mentions for Scinai Immunotherapeutics. Decoy Therapeutics' average media sentiment score of 0.22 beat Scinai Immunotherapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Neutral
Scinai Immunotherapeutics	Neutral

Scinai Immunotherapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-395.42%	-193.30%
Scinai Immunotherapeutics	N/A	N/A	N/A

Summary

Scinai Immunotherapeutics beats Decoy Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNI vs. The Competition

Export

Metric	Scinai Immunotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.26	21.61	28.02	24.70
Price / Sales	0.88	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.35	8.66	10.96	6.46
Net Income	-$8.31M	$23.81M	$3.57B	$337.01M
7 Day Performance	7.73%	3.39%	2.12%	1.69%
1 Month Performance	-34.42%	10.81%	5.25%	3.81%
1 Year Performance	-87.71%	62.61%	33.29%	23.90%

Scinai Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNI Scinai Immunotherapeutics	0.7331 of 5 stars	$0.27 flat	N/A	-87.7%	$1.07M	$1.21M	N/A	20	Upcoming Earnings
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.81 -2.1%	N/A	-59.7%	$4.31M	$290K	0.00	210	Positive News Short Interest Decrease Gap Up
ALZN Alzamend Neuro	3.6122 of 5 stars	$1.16 +3.6%	$28.00 +2,313.8%	-60.9%	$4.26M	N/A	N/A	4	Positive News Gap Down
CAPS Capstone Therapeutics	0.8771 of 5 stars	$0.26 -4.7%	N/A	-82.7%	$4.17M	$48.11M	N/A	38	Positive News Analyst Upgrade
REVB Revelation Biosciences	0.968 of 5 stars	$1.08 +3.8%	N/A	-88.1%	$4.06M	N/A	N/A	10	Positive News Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. RDHL, ALZN, CAPS, REVB, and DCOY

How does Scinai Immunotherapeutics compare to Redhill Biopharma?

Summary

How does Scinai Immunotherapeutics compare to Alzamend Neuro?

Summary

How does Scinai Immunotherapeutics compare to Capstone Therapeutics?

Summary

How does Scinai Immunotherapeutics compare to Revelation Biosciences?

Summary

How does Scinai Immunotherapeutics compare to Decoy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. RDHL, ALZN, CAPS, REVB, and DCOY

How does Scinai Immunotherapeutics compare to Redhill Biopharma?

Do analysts prefer RDHL or SCNI?

Which has preferable valuation and earnings, RDHL or SCNI?

Do institutionals and insiders have more ownership in RDHL or SCNI?

Is RDHL or SCNI more profitable?

Does the media prefer RDHL or SCNI?

Which has more risk & volatility, RDHL or SCNI?

Summary

How does Scinai Immunotherapeutics compare to Alzamend Neuro?

Is SCNI or ALZN more profitable?

Does the media refer more to SCNI or ALZN?

Which has higher valuation and earnings, SCNI or ALZN?

Do institutionals & insiders believe in SCNI or ALZN?

Do analysts prefer SCNI or ALZN?

Which has more risk and volatility, SCNI or ALZN?

Summary

How does Scinai Immunotherapeutics compare to Capstone Therapeutics?

Do insiders and institutionals have more ownership in SCNI or CAPS?

Does the media favor SCNI or CAPS?

Is SCNI or CAPS more profitable?

Do analysts rate SCNI or CAPS?

Which has more risk & volatility, SCNI or CAPS?

Which has higher earnings and valuation, SCNI or CAPS?

Summary

How does Scinai Immunotherapeutics compare to Revelation Biosciences?

Is SCNI or REVB more profitable?

Which has more risk & volatility, SCNI or REVB?

Do insiders & institutionals believe in SCNI or REVB?

Do analysts recommend SCNI or REVB?

Which has better earnings & valuation, SCNI or REVB?

Does the media refer more to SCNI or REVB?

Summary

How does Scinai Immunotherapeutics compare to Decoy Therapeutics?

Which has better valuation & earnings, DCOY or SCNI?

Do analysts rate DCOY or SCNI?

Which has more risk and volatility, DCOY or SCNI?

Do insiders and institutionals hold more shares of DCOY or SCNI?

Does the media favor DCOY or SCNI?

Is DCOY or SCNI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools